Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series)
Background: Trigeminal neuralgia is one of the most disabling facial pain syndromes. In recent years' new therapeutic strategy, incobotulinumtoxin A has emerged. The aim of the current study was to determine the time and duration of pain in 3 cases with pharmacological treatment and incobotulin...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Babol University of Medical Sciences
2023-03-01
|
| Series: | Caspian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://caspjim.com/article-1-3161-en.html |
| _version_ | 1797834432057442304 |
|---|---|
| author | Meghdad Hosseini Farhad Asarzadegan Erfan Shafiee Shayan Alijanpour |
| author_facet | Meghdad Hosseini Farhad Asarzadegan Erfan Shafiee Shayan Alijanpour |
| author_sort | Meghdad Hosseini |
| collection | DOAJ |
| description | Background: Trigeminal neuralgia is one of the most disabling facial pain syndromes. In recent years' new therapeutic strategy, incobotulinumtoxin A has emerged. The aim of the current study was to determine the time and duration of pain in 3 cases with pharmacological treatment and incobotulinumtoxin A.
Case presentation: In three patients with different onsets, trigeminal neuralgia was diagnosed. Pain severity was assessed by the visual analogue scale. Patient demographics and clinical data were filled in a checklist. They were females with age ranging from 39 to 49 years. Two patients had normal MRI and one patient had no any recent MRI. One center and specialist injection Xeomin 50 units for one time. Despite long time oral treatment, their symptoms had no significant improvement, but after incobotulinumtoxin A injection, pain frequency, severity and duration decreased in patients.
Conclusion: Result showed that the frequency, severity and duration of pain attacks was efficiently decreased by incobotulinumtoxin A with low side-effects. Its complication and side-effect should be considered in the future. |
| first_indexed | 2024-04-09T14:37:50Z |
| format | Article |
| id | doaj.art-57430089438441d3953a56b30b1a4c35 |
| institution | Directory Open Access Journal |
| issn | 2008-6164 2008-6172 |
| language | English |
| last_indexed | 2024-04-09T14:37:50Z |
| publishDate | 2023-03-01 |
| publisher | Babol University of Medical Sciences |
| record_format | Article |
| series | Caspian Journal of Internal Medicine |
| spelling | doaj.art-57430089438441d3953a56b30b1a4c352023-05-03T10:46:23ZengBabol University of Medical SciencesCaspian Journal of Internal Medicine2008-61642008-61722023-03-01142376379Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series)Meghdad Hosseini0Farhad Asarzadegan1Erfan Shafiee2Shayan Alijanpour3 Department of Neurology, Shahid Beheshti University of Medical Science, Tehran, Iran Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Student Research Committee, Faculty of Nursing and midwifery, Tehran University of Medical Science, Tehran, Iran Background: Trigeminal neuralgia is one of the most disabling facial pain syndromes. In recent years' new therapeutic strategy, incobotulinumtoxin A has emerged. The aim of the current study was to determine the time and duration of pain in 3 cases with pharmacological treatment and incobotulinumtoxin A. Case presentation: In three patients with different onsets, trigeminal neuralgia was diagnosed. Pain severity was assessed by the visual analogue scale. Patient demographics and clinical data were filled in a checklist. They were females with age ranging from 39 to 49 years. Two patients had normal MRI and one patient had no any recent MRI. One center and specialist injection Xeomin 50 units for one time. Despite long time oral treatment, their symptoms had no significant improvement, but after incobotulinumtoxin A injection, pain frequency, severity and duration decreased in patients. Conclusion: Result showed that the frequency, severity and duration of pain attacks was efficiently decreased by incobotulinumtoxin A with low side-effects. Its complication and side-effect should be considered in the future.http://caspjim.com/article-1-3161-en.htmltrigeminalneuralgiapainiran. |
| spellingShingle | Meghdad Hosseini Farhad Asarzadegan Erfan Shafiee Shayan Alijanpour Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series) Caspian Journal of Internal Medicine trigeminal neuralgia pain iran. |
| title | Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series) |
| title_full | Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series) |
| title_fullStr | Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series) |
| title_full_unstemmed | Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series) |
| title_short | Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series) |
| title_sort | trigeminal neuralgia incobotulinumtoxina xeomin can it decrease the pharmacological intervention a case series |
| topic | trigeminal neuralgia pain iran. |
| url | http://caspjim.com/article-1-3161-en.html |
| work_keys_str_mv | AT meghdadhosseini trigeminalneuralgiaincobotulinumtoxinaxeomincanitdecreasethepharmacologicalinterventionacaseseries AT farhadasarzadegan trigeminalneuralgiaincobotulinumtoxinaxeomincanitdecreasethepharmacologicalinterventionacaseseries AT erfanshafiee trigeminalneuralgiaincobotulinumtoxinaxeomincanitdecreasethepharmacologicalinterventionacaseseries AT shayanalijanpour trigeminalneuralgiaincobotulinumtoxinaxeomincanitdecreasethepharmacologicalinterventionacaseseries |